GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy), liraglutide, and tirzepatide (Mounjaro), are among the most prescribed medications in the world today. Millions of people use them for type 2 diabetes management and weight loss. But a critical question is only now entering clinical conversations: what do these medications do to your eyes?
I am a fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator with over 25 years of experience. My clinical approach focuses on identifying risk before damage is irreversible, simplifying treatment decisions, and protecting vision long-term. Emphasis on early detection, risk assessment, and continuity of care.
I have co-authored two peer-reviewed Pubmed indexed publications on exactly this question, both published in the Journal of Current Glaucoma Practice. This article reflects what the current evidence actually shows, not headlines, not speculation.
What Are GLP-1 Receptor Agonists?
GLP-1 receptor agonists mimic a gut hormone called glucagon-like peptide-1. They lower blood sugar, reduce appetite, and slow digestion. Medications in this class include semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), and tirzepatide (Mounjaro).
Their popularity has grown rapidly. In India, prescriptions for these medications have increased significantly as their benefits for diabetes control and weight loss become more widely known. Many patients start them without any baseline eye evaluation.
That is a missed opportunity, and in some cases, a risk.
Here is a short paragraph — drop it in after the “What Are GLP-1 Receptor Agonists?” section:
Generic Semaglutide in India: What the New Availability Means
Semaglutide has recently come off patent in several markets, and generic versions are now entering India at significantly lower price points than branded Ozempic or Wegovy. This is expected to accelerate uptake rapidly — making this medication accessible to a far larger population than before. Branded semaglutide was priced beyond reach for most Indian patients. Generic versions change that. More patients starting semaglutide also means more patients who need baseline eye evaluations. If you are considering a generic semaglutide prescription, the guidance in this article applies equally. The molecule is the same. So is the need for an eye check before you begin.
Two Published Perspectives on GLP-1 Agonists and Glaucoma
The science on this topic is moving fast. I want to share what our research group has contributed.
In early 2025, I co-authored an editorial in the Journal of Current Glaucoma Practice titled “GLP-1 Receptor Agonists, Allostatic Load, and Reframing the Glaucoma Paradigm” (Bhartiya S, Dorairaj SK. PMID 40417146). This piece argued that GLP-1 agonists represent more than a metabolic intervention. They address the systemic allostatic load, the cumulative burden of chronic stress and disease on the body, that underlies glaucoma progression. The editorial called for a broader, more integrated framework for understanding glaucoma risk.
Later in 2025, a more comprehensive review was published in the same journal: “Glaucoma Risk Reduction as a Secondary Benefit of Glucagon-like Peptide-1 Receptor Agonists: A Review of Emerging Evidence” (Lang MV, Vasu P, Dorairaj EA, Bhartiya S, Dorairaj SK. PMID 41523168). This systematic review analysed nine studies meeting rigorous inclusion criteria. Most studies found a statistically significant association between GLP-1 receptor agonist use and reduced glaucoma risk. Stronger protective effects were seen with longer duration of use in three studies. Proposed mechanisms include lowering of intraocular pressure, reduction of oxidative stress, and direct neuroprotection through GLP-1 receptor activation in ocular tissues.
One preclinical study showed that a GLP-1 receptor agonist protected retinal ganglion cells and reduced neuroinflammation in a mouse model. Retinal ganglion cells are the nerve cells lost in glaucoma. This finding has significant implications.
However, and this is important, the review also noted that most existing studies are retrospective. Randomised controlled trials are still needed. One Mendelian randomisation study did not support a causal link. The evidence is promising, not conclusive.
The NAION Question: Is There a Risk?
Alongside the evidence for potential protection, a separate concern has emerged. In 2024, a study from Harvard Medical School identified a possible association between semaglutide use and nonarteritic anterior ischaemic optic neuropathy (NAION) — a condition involving sudden vision loss due to reduced blood supply to the optic nerve.
This finding generated significant international attention and led to calls for closer ophthalmological monitoring in high-risk patients. The risk appears to be concentrated in patients with pre-existing optic nerve changes, diabetes, or cardiovascular risk factors.
The picture is genuinely nuanced. GLP-1 agonists may reduce the risk of glaucoma through neuroprotective mechanisms. They may simultaneously carry a small but real risk of NAION in vulnerable individuals. These are not contradictory findings. They reflect the complexity of how a powerful systemic medication interacts with ocular physiology.
This is precisely why a baseline eye evaluation matters.
GLP-1 Agonists and Diabetic Retinopathy
Rapid improvement in blood sugar control, which GLP-1 agonists produce effectively, can temporarily worsen diabetic retinopathy. This is a well-documented phenomenon called early worsening of diabetic retinopathy. It is more likely in patients with longer duration of diabetes or previously poor glucose control.
If you have diabetes and are starting a GLP-1 agonist, a retinal evaluation before you begin is essential.
Why Your Eyes Need a Baseline Before You Start
Your eyes are among the most metabolically active tissues in your body. They are also directly affected by the conditions GLP-1 agonists treat: diabetes, obesity, hypertension, and metabolic syndrome. Each of these independently raises your risk for glaucoma, diabetic retinopathy, and other sight-threatening diseases.
Starting a GLP-1 agonist without a baseline eye evaluation means you have no reference point. If a concern appears six months later, you cannot know whether the medication contributed to it, whether it was already present, or whether it is unrelated.
A baseline evaluation takes less than an hour. It can protect you for years.
Who Needs a Pre-Treatment Eye Evaluation?
You need an eye evaluation before starting a GLP-1 agonist if you have any of the following: a diagnosis of type 2 diabetes or prediabetes; a family history of glaucoma; previously raised eye pressure or a glaucoma suspect diagnosis; any existing eye disease including diabetic retinopathy, macular degeneration, or optic nerve changes; obesity with associated hypertension or metabolic syndrome; a history of cardiovascular disease; or age over 40 with no recent comprehensive eye examination.
If none of these apply, a baseline evaluation is still advisable. It establishes a reference point that protects you if any concern arises later.
What the Evaluation Includes
A pre-GLP-1 eye evaluation at my clinic includes the following, apart from vision, refraction and colour vision assessments.
Intraocular pressure measurement checks the fluid pressure inside your eye. Raised pressure is a major risk factor for glaucoma.
Optic nerve evaluation examines the structure most vulnerable in both glaucoma and NAION. I assess it directly and with imaging where indicated.
Visual field assessment, if needed, maps your peripheral vision. Glaucoma damages peripheral vision first, often before you notice anything wrong.
Retinal evaluation screens for diabetic retinopathy, macular changes, and other structural problems.
Cup-to-disc ratio, and neuro-retinal rim health documentation gives us a baseline measurement of your optic nerve head for comparison at future visits.
The full evaluation typically takes 45 to 60 minutes.
How Often Should You Have Follow-Up Eye Examinations?
For patients with no risk factors and a normal baseline evaluation, an annual eye examination is appropriate.
For patients with diabetes, raised eye pressure, glaucoma, or other risk factors, more frequent monitoring, every six months, is advisable, particularly in the first year when blood sugar changes are most rapid.
If you experience any sudden change in vision, pain in or around the eye, new blind spots, or visual disturbance while on a GLP-1 agonist, seek urgent ophthalmological review. Do not wait for your next scheduled appointment.
A Note on Second Opinions
Many patients come to me after starting a GLP-1 agonist because their prescribing doctor did not mention eye health. Endocrinologists, diabetologists, and general physicians prescribe these medications for metabolic reasons. Eye health falls outside their primary scope.
If you have already started a GLP-1 agonist and have not had an eye evaluation, it is not too late. A baseline now still provides valuable information and establishes the reference point we need for your ongoing care.
Frequently Asked Questions
Can Ozempic damage your eyes?
Research published in 2024 identified a possible association between semaglutide (Ozempic) and nonarteritic anterior ischaemic optic neuropathy (NAION), a condition causing sudden vision loss due to reduced blood supply to the optic nerve. The risk appears higher in patients with pre-existing optic nerve changes, diabetes, or cardiovascular risk factors. An ophthalmological evaluation before starting Ozempic is advisable for anyone in these categories.
Can GLP-1 agonists actually protect against glaucoma?
Emerging evidence suggests they may. A 2025 systematic review published in the Journal of Current Glaucoma Practice (PMID 41523168), co-authored by our research group at Mayo Clinic and Marengo Asia Hospitals, found that most studies identified a statistically significant association between GLP-1 receptor agonist use and reduced glaucoma risk. Proposed mechanisms include lowering of intraocular pressure, reduction of oxidative stress, and direct neuroprotection through GLP-1 receptors in the eye. Randomised controlled trials are still needed.
Should I see an eye doctor before starting Mounjaro or Ozempic?
Yes, particularly if you have diabetes, a family history of glaucoma, raised eye pressure, or any existing eye disease. A baseline evaluation establishes a reference point for ongoing monitoring and helps identify pre-existing conditions that need closer follow-up during treatment.
Can rapid blood sugar control worsen diabetic eye disease?
Yes. Rapid improvement in blood glucose can temporarily worsen diabetic retinopathy. This is well documented and more likely in patients with longer duration of diabetes or previously poor blood sugar control. A retinal evaluation before starting treatment is essential for diabetic patients.
What eye symptoms should I watch for on GLP-1 therapy?
Seek urgent eye review if you experience sudden vision loss in one or both eyes, new blind spots, blurred vision that does not resolve, pain behind or around the eye, or any sudden change in your vision. These symptoms need same-day evaluation.
Is there a glaucoma specialist in Gurgaon who offers this evaluation?
Yes. I offer pre-GLP-1 eye screening at Marengo Asia Hospitals, Sector 56, Gurugram. The evaluation includes intraocular pressure measurement, optic nerve assessment, visual field testing, and retinal screening. Book at www.drshibalbhartiya.com or call +91 88826 38735.
The Bottom Line
GLP-1 receptor agonists are effective, widely prescribed medications. Emerging evidence suggests they may carry a secondary benefit for glaucoma risk, and a small but real concern for optic nerve blood supply in vulnerable patients. Both findings point to the same conclusion: patients starting these medications need a baseline eye evaluation and ongoing monitoring.
A one-hour assessment before you begin treatment is a small investment in the long-term protection of your vision.
If you are in Gurgaon or the Delhi NCR region and starting a GLP-1 agonist, I am happy to see you for a pre-treatment evaluation or a second opinion.
Read the research articles
This article was written by Dr Shibal Bhartiya, fellowship-trained glaucoma specialist and Mayo Clinic Research Collaborator, Clinical Director at Marengo Asia Hospitals, Gurugram, known for ethical, patient-centred glaucoma care and independent glaucoma second opinions. This article was edited in April 2026.
She has published peer-reviewed research on glaucoma management, examining how treatment decisions should balance medical evidence, patient preferences, and long-term vision outcomes.
As Editor-in-Chief of Clinical and Experimental Vision and Eye Research and Executive Editor of the Journal of Current Glaucoma Practice (Pubmed Indexed, official journal of the International Society of Glaucoma Surgery), Dr Shibal Bhartiya brings editorial and research depth to every clinical decision. Her 200+ publications, including 90+ PubMed-indexed publications and 28 edited textbooks span glaucoma biology, surgical outcomes, health equity, and emerging diagnostics.
Her work can be accessed on Pubmed, Google Scholar, ResearchGate and ORCID.
Dr Shibal Bhartiya
Glaucoma • Second Opinion • Advanced Care
www.drshibalbhartiya.com
+91 88826 38735
1500+ Five Star Patient Reviews Google Business Profile
